← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
J.David Gladstone Institutes
$13,681,388
Total funding
14
Grants
Funding over time
peak $3.4M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$13,681,388 · 14
By mechanism
—$13,681,388 · 14
Investigators at J.David Gladstone Institutes
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A NOVEL APPROACH FOR PREVENTING HIV INFECTION AND REDUCING RISK TO U.S. MILITARY PERSONNEL$2,614,289
· FY2011 · Department of Defense
MOLECULAR MECHANISMS OF TRANSCRIPTION FACTOR DOSAGE IN HEART DEVELOPMENT AND CONGENITAL HEART DISEASE$2,258,909
· FY2017 · Department of the Army
DEVELOPMENT OF NOVEL NEURONAL AUTOPHAGY INDUCERS TO BLOCK NEURODEGENERATION AND TREAT ALS$1,537,103
· FY2015 · Department of the Army
FIBRIN AS AN INHIBITOR OF REMYELINATION: MECHANISMS, FUNCTIONS, AND THERAPEUTIC APPLICATIONS IN MULTIPLE SCLEROSIS.$1,132,261
· FY2017 · Department of the Army
NEW AWARD - DEVELOPING SMALL MOLECULE THERAPEUTICS FOR PREVENTING POST-TRAUMATIC EPILEPSY SIGNED 12-MAY-2020, EFFECTIVE 15 MAY 2020, DISTRIBUTED MAY 13, 2020, FAADC 5/13/2020$942,483
· FY2020 · Defense Health Agency
DECONSTRUCTION AND CONTROL OF NEURAL CIRCUITS IN POSTTRAUMATIC EPILEPSY$875,289
· FY2016 · Department of Defense
GENETIC VARIANTS CONFERRING SUSCEPTIBILITY TO TOXICANT-INDUCED PARKINSON'S DISEASE$811,942
· FY2024 · Defense Health Agency
IMPACT OF ENERGY FAILURE ON ALPHA-SYNUCLEIN SPREAD AND NEURODEGENERATION$751,936
· FY2022 · Department of the Army
EXOSOME-MEDIATED TRANSMISSION OF NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS USING PATIENT-INDUCED PLURIPOTENT STEM CELL-DERIVED NEURONS AND A$719,725
· FY2014 · Department of Defense
VALIDATING UBC9 AS A MOLECULAR TARGET TO DEVELOP A THERAPY FOR ALL FORMS OF ALS$687,779
· FY2018 · Department of the Army
REGULATORS OF CYTOPLASMIC TDP43 CONDENSATES AS THERAPEUTIC TARGETS.$666,472
· FY2022 · Defense Health Agency
THE ROLE OF EPIGENETICS AND METHYLATION NEAR THE DMPK GENE IN CAUSING NEURODEGENERATION IN MYOTONIC DYSTROPHY TYPE 1$377,600
· FY2019 · Department of the Army
CHEMICAL STRATEGY TO TRANSLATE GENETIC/EPIGENETIC MECHANISMS TO BREAST CANCER THERAPEUTICS$305,600
· FY2011 · Department of the Army
MECHANISMS OF PARKINSON'S WITH DEMENTIA$0
· FY2025 · Defense Health Agency